Press Release

Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference

WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Canaccord Genuity’s 38th Annual Growth Conference on August 8, 2018 at 1:30 PM EDT at the InterContinental Boston Waterfront, Boston, MA. 

To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here.  The webcasts will be available for approximately 45 days following the respective conferences.

About Histogenics Corporation

Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.  Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis.  NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.  Histogenics completed enrollment of its NeoCart Phase 3 clinical trial in the second quarter of 2017 and expects to report top-line, one-year superiority data in the third quarter of 2018.  NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.  For more information on Histogenics and NeoCart, please visit www.histogenics.com.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com

Primary Logo

Histogenics Corporation